Ernexa Therapeutics membuat kemajuan signifikan dengan kandidat obat kanker utama mereka, ERNA-101, yang dijadwalkan untuk pengajuan Investigational New Drug (IND) pada kuartal ketiga tahun 2026. Perusahaan ini bertujuan untuk memulai studi klinis fase 1 pada kuartal keempat tahun 2026, menandai transisi mereka menjadi perusahaan bioteknologi tahap klinis. Data praklinis menunjukkan bahwa ERNA-101, terutama bila dikombinasikan dengan penghambat PD-1, secara efektif menghilangkan tumor dan meningkatkan kelangsungan hidup jangka panjang pada model kanker ovarium, menunjukkan potensinya untuk mengatasi tumor "dingin" secara imunologis. Dengan pendanaan yang kuat, Ernexa siap untuk mencapai beberapa tonggak penting hingga tahun 2027, termasuk data klinis awal dan potensi kemitraan.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
